Shots:

• The approval is based on P-IIIa studies (NCT03099096 & NCT03021304) assessing Nucala in-clinic and at home for patients with severe eosinophilic asthma (SEA). Additionally- a study (NCT03014674) evaluated Nucala’s PK and PD via auto-injector & pre-filled syringe was comparable with approved lyophilised formulation
• The study resulted in 89-95% and 100% successful self-administered treatment with autoinjector and pre-filled syringe respectively post training of patients
• Nucala is a mAb that targets interleukin-5 (IL-5) available as an autoinjector/pre-filled syringe administered q4w and is approved in EU for pediatric patients aged 6 to 17 yrs. for SAE and in the US- Japan & Canada as an add-on maintenance treatment for EGPA

Ref: GSK | Image: GSK